Published in Diabetes Care on May 18, 2010
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17
A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in patients with uncontrolled type 2 diabetes. Diabetes Care (2013) 1.81
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nat Genet (2016) 1.48
Quantifying the effect of metformin treatment and dose on glycemic control. Diabetes Care (2012) 1.02
Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. Diabetes Metab Syndr Obes (2012) 0.91
Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study. Diabetes Res Clin Pract (2016) 0.88
Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis. Diabetologia (2013) 0.87
A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes Metab Res Rev (2014) 0.87
Pharmacogenetics of oral antidiabetic drugs. Int J Endocrinol (2013) 0.86
The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study. Clin Exp Med (2014) 0.86
Using simulation technology to teach diabetes care management skills to resident physicians. J Diabetes Sci Technol (2013) 0.85
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. J Korean Med Sci (2013) 0.83
Standards of care for type 2 diabetes in China. Diabetes Metab Res Rev (2016) 0.82
Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients. Cardiovasc Diabetol (2015) 0.80
Reaction time in adolescence, cumulative allostatic load, and symptoms of anxiety and depression in adulthood: the West of Scotland Twenty-07 Study. Psychosom Med (2015) 0.79
Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data. Br J Clin Pharmacol (2014) 0.78
Effect of telemedicine on glycated hemoglobin in diabetes: a systematic review and meta-analysis of randomized trials. CMAJ (2016) 0.78
Four-Year Durability of Initial Combination Therapy with Sitagliptin and Metformin in Patients with Type 2 Diabetes in Clinical Practice; COSMIC Study. PLoS One (2015) 0.78
The importance of age, sex and place in understanding socioeconomic inequalities in allostatic load: Evidence from the Scottish Health Survey (2008-2011). BMC Public Health (2016) 0.78
A review of the treatment of type 2 diabetes in children. J Pediatr Pharmacol Ther (2015) 0.77
Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes. J Clin Med Res (2015) 0.76
Thyroid function and autoimmunity are associated with the risk of vertebral fractures in postmenopausal women. J Bone Miner Metab (2016) 0.76
Clinical Outcomes of Continuation of Metformin Titration Instructions with Electronic Prescribing. Drugs Real World Outcomes (2015) 0.75
Are diabetes management guidelines applicable in 'real life'? Diabetol Metab Syndr (2012) 0.75
Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38). J Diabetes Investig (2015) 0.75
Treatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonists. Diabetes Metab Res Rev (2016) 0.75
Pilot Study of Caffeine Abstinence for Control of Chronic Glucose in Type 2 Diabetes. J Caffeine Res (2012) 0.75
Impact of ATM and SLC22A1 Polymorphisms on Therapeutic Response to Metformin in Iranian Diabetic Patients. Int J Mol Cell Med (2016) 0.75
The role of bile acid sequestrants in the management of type 2 diabetes mellitus. Metab Syndr Relat Disord (2010) 0.75
Glycemic control: a combination of lifestyle management and the use of drugs. Cardiol Ther (2012) 0.75
Efficacy and Safety of Evogliptin Monotherapy in Patients with Type 2 Diabetes and Moderately Elevated HbA1c by Diet and Exercise. Diabetes Obes Metab (2017) 0.75
Allostatic load as a predictor of all-cause and cause-specific mortality in the general population: Evidence from the Scottish Health Survey. PLoS One (2017) 0.75
Participation in a farmers' market fruit and vegetable prescription program at a federally qualified health center improves hemoglobin A1C in low income uncontrolled diabetics. Prev Med Rep (2017) 0.75
Dulce Digital: An mHealth SMS-Based Intervention Improves Glycemic Control in Hispanics With Type 2 Diabetes. Diabetes Care (2017) 0.75
Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care (2006) 9.87
Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA (2002) 5.00
Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care (2005) 2.71
Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev (2005) 2.41
Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care (2006) 2.19
Characterization of glycosylated hemoglobins. Relevance to monitoring of diabetic control and analysis of other proteins. J Clin Invest (1983) 1.29
A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther (2001) 1.20
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study. Lancet (2010) 4.53
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care (2014) 3.31
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol (2011) 3.25
Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab (2004) 2.86
Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet (2009) 2.79
Acute rehabilitation practices in critically ill children: a multicenter study. Pediatr Crit Care Med (2014) 2.71
Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J Am Coll Cardiol (2010) 2.66
Association of vitamin D with insulin resistance and beta-cell dysfunction in subjects at risk for type 2 diabetes. Diabetes Care (2010) 2.61
Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care (2010) 2.42
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation (2005) 2.39
Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. Circulation (2009) 1.99
Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care (2003) 1.93
Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J (2013) 1.92
Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients. Kidney Int (2011) 1.91
A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. Diabetes Care (2007) 1.76
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care (2013) 1.71
Computerized clinical decision support systems for chronic disease management: a decision-maker-researcher partnership systematic review. Implement Sci (2011) 1.70
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol (2010) 1.68
Glycosylated hemoglobin: finally ready for prime time as a cardiovascular risk factor. Ann Intern Med (2004) 1.64
Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens (2013) 1.62
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). J Am Coll Cardiol (2009) 1.54
Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care (2012) 1.51
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care (2010) 1.50
Insulin therapy in acute coronary syndromes: an appraisal of completed and ongoing randomised trials with important clinical end points. Diab Vasc Dis Res (2008) 1.48
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Long-term consequences of fetal and neonatal nicotine exposure: a critical review. Toxicol Sci (2010) 1.45
Despite 2009 guidelines, few women report being counseled correctly about weight gain during pregnancy. Am J Obstet Gynecol (2011) 1.45
Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care (2005) 1.42
Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trial. Diabetologia (2014) 1.42
Obesity genes and risk of major depressive disorder in a multiethnic population: a cross-sectional study. J Clin Psychiatry (2015) 1.41
Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care (2002) 1.40
Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J (2010) 1.39
Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). PLoS One (2011) 1.38
Comparing methods to estimate treatment effects on a continuous outcome in multicentre randomized controlled trials: a simulation study. BMC Med Res Methodol (2011) 1.34
Analysis of health utility data when some subjects attain the upper bound of 1: are Tobit and CLAD models appropriate? Value Health (2010) 1.32
Association of 25(OH)D and PTH with metabolic syndrome and its traditional and nontraditional components. J Clin Endocrinol Metab (2010) 1.28
Kidney disease after preeclampsia: a systematic review and meta-analysis. Am J Kidney Dis (2010) 1.23
Reproducibility of impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) classification: a systematic review. Clin Chem Lab Med (2007) 1.18
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol (2003) 1.18
The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care (2004) 1.18
Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. J Clin Endocrinol Metab (2009) 1.13
Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation (2011) 1.12
Fetal and neonatal nicotine exposure in Wistar rats causes progressive pancreatic mitochondrial damage and beta cell dysfunction. PLoS One (2008) 1.12
Increased pancreatic beta-cell apoptosis following fetal and neonatal exposure to nicotine is mediated via the mitochondria. Toxicol Sci (2008) 1.07
Maternal nicotine exposure increases oxidative stress in the offspring. Free Radic Biol Med (2008) 1.07
Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. Diabetes Res Clin Pract (2007) 1.06
Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada. Can J Cardiol (2010) 1.03
Association of depression with accelerated cognitive decline among patients with type 2 diabetes in the ACCORD-MIND trial. JAMA Psychiatry (2013) 1.02
Impact of a computerized system for evidence-based diabetes care on completeness of records: a before-after study. BMC Med Inform Decis Mak (2012) 1.01
Relationship of epicardial fat thickness and fasting glucose. Int J Cardiol (2008) 1.00
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women. BMC Musculoskelet Disord (2011) 0.99
Prevalence and predictors of exclusive breastfeeding at hospital discharge. Obstet Gynecol (2012) 0.98
Shared electronic vascular risk decision support in primary care: Computerization of Medical Practices for the Enhancement of Therapeutic Effectiveness (COMPETE III) randomized trial. Arch Intern Med (2011) 0.98
Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. Diabetes Care (2009) 0.98
Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. Kidney Int (2004) 0.98
Dysglycemia and a history of reproductive risk factors. Diabetes Care (2008) 0.97
"I take what I think works for me": a qualitative study to explore patient perception of diabetes treatment benefits and risks. Can J Clin Pharmacol (2007) 0.97
Prospective associations of vitamin D with β-cell function and glycemia: the PROspective Metabolism and ISlet cell Evaluation (PROMISE) cohort study. Diabetes (2011) 0.96
Glycemic index predicts individual glucose responses after self-selected breakfasts in free-living, abdominally obese adults. J Nutr (2011) 0.96
A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Med Care (2016) 0.94
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. Diabetes Care (2009) 0.93
Comparing EQ-5D valuation studies: a systematic review and methodological reporting checklist. Med Decis Making (2013) 0.93
Do lifestyle changes reduce serious outcomes in diabetes? N Engl J Med (2013) 0.92
Fetal and neonatal nicotine exposure and postnatal glucose homeostasis: identifying critical windows of exposure. J Endocrinol (2007) 0.92
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. Am J Kidney Dis (2003) 0.91
Estimation of the impact of diabetes-related complications on health utilities for patients with type 2 diabetes in Ontario, Canada. Qual Life Res (2011) 0.91
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. Diabetes Care (2010) 0.87
Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl (2004) 0.87
Prospective association of 25(OH)D with metabolic syndrome. Clin Endocrinol (Oxf) (2013) 0.87
Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care (2013) 0.87
Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. Diabetes Care (2012) 0.86
Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial. BMC Infect Dis (2014) 0.86
Cardiovascular risk in patients with mild renal insufficiency. Kidney Int Suppl (2003) 0.86
Can community retail pharmacist and diabetes expert support facilitate insulin initiation by family physicians? Results of the AIM@GP randomized controlled trial. BMC Health Serv Res (2013) 0.85
Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis. AIDS Res Ther (2013) 0.85
Transgenerational effects of fetal and neonatal exposure to nicotine. Endocrine (2007) 0.85
Short leg length, a marker of early childhood deprivation, is associated with metabolic disorders underlying type 2 diabetes: the PROMISE cohort study. Diabetes Care (2013) 0.85
Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. Am Heart J (2009) 0.85
Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). Diabetes Care (2013) 0.85
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. Diabetologia (2014) 0.84
Does genetic heterogeneity account for the divergent risk of type 2 diabetes in South Asian and white European populations? Diabetologia (2014) 0.84
Data withdrawal in randomized controlled trials: Defining the problem and proposing solutions: a commentary. Contemp Clin Trials (2011) 0.84